DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 2542--------------------------------------------------
       (Abst.) Long-term disease activity and disability progression in
        RRMS patients on Tysabri
       By: agate Date: June 8, 2019, 1:32 pm
       ---------------------------------------------------------
       Not much information about just how the patients taking Tysabri
       (or other MS drugs) are doing over time but this research
       concludes:
       [quote][font=arial]When taking into account early inflammation
       and the impact of natalizumab on disease activity during the
       initial treatment phase, a higher than expected proportion of
       patients showed disability progression.[/font]
       [/quote]
       From PubMed, June 8, 2019--"Long-term disease activity and
       disability progression in RRMS patients on natalizumab" by
       researchers in Amsterdam, including two who are well known in MS
       research--Barkhof, Uitdehaag:
  HTML https://www.ncbi.nlm.nih.gov/pubmed/31174043
       *****************************************************